MRM Health Raises €55 Million Series B to Advance Best-in-Class Microbiome-Based Biotherapeutic Product Pipeline
GHENT, Belgium -- MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced the successful closing of a €55 million (US$64 million) Series B financing round. Read More
Recent Posts
Trump says Netflix deal to buy Warner Bros. ‘could be a problem’ because of size of market share
Pulsar Helium Reports Pressurised Gas Encounter at Jetstream #5 and Down-Hole Testing Conducted at Jetstream #3 and #4
SHELL PLC THIRD QUARTER 2025 EURO AND GBP EQUIVALENT DIVIDEND PAYMENTS
ECB’s Schnabel ‘Comfortable’ on Bets Next Move Will Be Hike
Galderma Welcomes Increased Equity Investment From L’Oréal
SNB Set to Avoid Negative Rate in Favor of ‘Lesser Evil’ for Now
Russia LNG Plant in Baltics Sends Sanctioned Gas to China
What to know about changes to Disney parks’ disability policies
India Sees New Nuclear Bill Spurring Projects Worth $214 Billion
China’s Benchmark Power-Station Coal Price to Stay Flat in 2026
